MNOV - MediciNova, Inc. Summary, Stock Quote and News

Market Overview

5.550 0.24 (4.52%)

After Hours 5.55 (%)

Data as of May 24, 2020

Prev. Close 5.31
Price Open 5.33
Volume 47,338
Day's Range 5.27 - 5.55
52 Wk Range 2.79 - 11.83
50 Day Moving Avg. 4.72
PE Ratio 0
Shares Outstanding 44.07M
Market Cap 244.58M

Trade MNOV stock for free with recommended broker TD Ameritrade.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
3/13/20	B. Riley FBR	Maintains	Buy	11.0
3/25/19	B. Riley FBR	Assumes	Buy	22.0
3/28/18	B. Riley FBR	Initiates Coverage On	Buy	22.0

MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma Charles GrossTue, 21 Apr 2020 06:14:23 -0400
78 Biggest Movers From Yesterday Lisa LevinWed, 15 Apr 2020 04:45:39 -0400
55 Stocks Moving In Tuesday's Mid-Day Session Lisa LevinTue, 14 Apr 2020 12:52:38 -0400
86 Biggest Movers From Yesterday Lisa LevinTue, 14 Apr 2020 05:19:14 -0400
63 Stocks Moving In Monday's Mid-Day Session Lisa LevinMon, 13 Apr 2020 12:35:37 -0400
100 Biggest Movers From Thursday Lisa LevinMon, 13 Apr 2020 05:18:21 -0400
75 Stocks Moving In Thursday's Mid-Day Session Lisa LevinThu, 09 Apr 2020 13:02:57 -0400
86 Biggest Movers From Yesterday Lisa LevinThu, 09 Apr 2020 05:43:43 -0400
65 Stocks Moving In Wednesday's Mid-Day Session Lisa LevinWed, 08 Apr 2020 12:35:54 -0400
MediciNova shares are trading higher after the company announced that it plans to initiate a clinical trial of MN-166 for coronavirus acute respiratory distress syndrome. Benzinga NewsdeskWed, 08 Apr 2020 08:53:43 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma Globe NewswireApr 20, 2020
Several Potential Coronavirus Vaccines and Treatments Progressing Towards Human Trials PRNewswireApr 13, 2020
MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS) Globe NewswireApr 08, 2020
MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS) Globe NewswireMar 09, 2020
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan Globe NewswireFeb 17, 2020
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe Globe NewswireJan 27, 2020
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia Globe NewswireDec 04, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada Globe NewswireOct 28, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan Globe NewswireOct 23, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan Globe NewswireOct 07, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

MediciNova Receives Notice of Allowance for Second Patent Covering MN-–66 (ibudilast) for the ... GuruFocusApr 20, 2020
MediciNova Receives Notice of Allowance for New Patent Covering MN-……– and MN-……— ... GuruFocusFeb 17, 2020
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-……– for the ... GuruFocusJan 27, 2020
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-–66 (ibudilast) ... GuruFocusDec 04, 2019
MediciNova nabs new Canadian patent covering ibudilast Seeking AlphaOct 28, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-……– for the Treatment ... GuruFocusOct 23, 2019
MediciNova nabs new patent in Japan for MN-001 Seeking AlphaOct 23, 2019
MediciNova nabs new patent for MN-001 and MN-002 in Japan Seeking AlphaOct 08, 2019
MediciNova Receives Notice of Allowance for New Patent Covering MN-……– and MN-……— ... GuruFocusOct 07, 2019
MediciNova to Present at the Ladenburg Thalmann —…–9 Healthcare Conference in New York GuruFocusSep 11, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q4 2019	EST	Actual	Surprise
EPS:	Expected 2020-02-13
Rev:	Expected 2020-02-13

Q1 2020	EST	Actual	Surprise
EPS:	Expected 2020-06-05
Rev:	Expected 2020-06-05

Company Profile

Start Investing

The Best Online Stock Trading Brokers

Best Free Stock Trading Brokers

Best Forex Brokers

Best Futures Brokers

How to Invest in Real Estate

Best Day Trading Courses

Brokerage Center

Compare All Online Brokerages

+

+

Market Overview

Tickers

Articles

Keywords

MediciNova, Inc. MNOV:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Start Investing

Brokerage Center